These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 26248957)

  • 21. Functional levels and MRI patterns of muscle involvement in upper limbs in Duchenne muscular dystrophy.
    Brogna C; Cristiano L; Tartaglione T; Verdolotti T; Fanelli L; Ficociello L; Tasca G; Battini R; Coratti G; Forcina N; De Santis R; Norcia G; Carnicella S; Colosimo C; Carlier P; Pane M; Mercuri E
    PLoS One; 2018; 13(6):e0199222. PubMed ID: 29924868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unraveling upper extremity performance in Duchenne muscular dystrophy: A biophysical model.
    Janssen MMHP; Harlaar J; Koopman B; de Groot IJM
    Neuromuscul Disord; 2019 May; 29(5):368-375. PubMed ID: 31029531
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Longitudinal pulmonary function testing outcome measures in Duchenne muscular dystrophy: Long-term natural history with and without glucocorticoids.
    McDonald CM; Gordish-Dressman H; Henricson EK; Duong T; Joyce NC; Jhawar S; Leinonen M; Hsu F; Connolly AM; Cnaan A; Abresch RT;
    Neuromuscul Disord; 2018 Nov; 28(11):897-909. PubMed ID: 30336970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reachable workspace and performance of upper limb (PUL) in duchenne muscular dystrophy.
    Han JJ; de Bie E; Nicorici A; Abresch RT; Anthonisen C; Bajcsy R; Kurillo G; Mcdonald CM
    Muscle Nerve; 2016 Apr; 53(4):545-54. PubMed ID: 26342193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Longitudinal Motor Functional Outcomes and Magnetic Resonance Imaging Patterns of Muscle Involvement in Upper Limbs in Duchenne Muscular Dystrophy.
    Brogna C; Cristiano L; Verdolotti T; Norcia G; Ficociello L; Ruiz R; Coratti G; Fanelli L; Forcina N; Petracca G; Chieppa F; Tartaglione T; Colosimo C; Pane M; Mercuri E
    Medicina (Kaunas); 2021 Nov; 57(11):. PubMed ID: 34833484
    [No Abstract]   [Full Text] [Related]  

  • 26. Functional abilities, respiratory and cardiac function in a large cohort of adults with Duchenne muscular dystrophy treated with glucocorticoids.
    Schiava M; Lofra RM; Bourke JP; Díaz-Manera J; James MK; Elseed MA; Malinova M; Michel-Sodhi J; Moat D; Ghimenton E; Mccallum M; Díaz CFB; Mayhew A; Wong K; Richardson M; Tasca G; Eglon G; Eagle M; Turner C; Heslop E; Straub V; Bettolo CM; Guglieri M
    Eur J Neurol; 2024 Jun; 31(6):e16267. PubMed ID: 38556893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functional trajectories before and after loss of ambulation in Duchenne muscular dystrophy and implications for clinical trials.
    McDonald CM; Signorovitch J; Mercuri E; Niks EH; Wong B; Fillbrunn M; Sajeev G; Yim E; Dieye I; Miller D; Ward SJ; Goemans N;
    PLoS One; 2024; 19(6):e0304099. PubMed ID: 38829874
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Test-retest reliability of the Performance of Upper Limb (PUL) module for muscular dystrophy patients.
    Gandolla M; Antonietti A; Longatelli V; Biffi E; Diella E; Delle Fave M; Rossini M; Molteni F; D'Angelo G; Bocciolone M; Pedrocchi A
    PLoS One; 2020; 15(9):e0239064. PubMed ID: 32986757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Association between the Respiratory System and Upper Limb Strength in Males with Duchenne Muscular Dystrophy: A New Field for Intervention?
    Sobierajska-Rek A; Wasilewska E; Śledzińska K; Jabłońska-Brudło J; Małgorzewicz S; Wasilewski A; Szalewska D
    Int J Environ Res Public Health; 2022 Nov; 19(23):. PubMed ID: 36497753
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RESPONSIVENESS OF UPPER LIMB SCALES AND TRUNK CONTROL FOR THE EVOLUTION OF PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY.
    Maciel FKL; Santos ALYDS; Sá CDSC
    Rev Paul Pediatr; 2021; 39():e2020045. PubMed ID: 33656143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy.
    Tian C; Wong BL; Hornung L; Khoury JC; Miller L; Bange J; Rybalsky I; Rutter MM
    Neuromuscul Disord; 2016 Nov; 26(11):760-767. PubMed ID: 27614576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect.
    Balaban B; Matthews DJ; Clayton GH; Carry T
    Am J Phys Med Rehabil; 2005 Nov; 84(11):843-50. PubMed ID: 16244521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Skeletal disproportion in glucocorticoid-treated boys with Duchenne muscular dystrophy.
    Kao KT; Joseph S; Capaldi N; Brown S; Di Marco M; Dunne J; Horrocks I; Shepherd S; Ahmed SF; Wong SC
    Eur J Pediatr; 2019 May; 178(5):633-640. PubMed ID: 30762116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of the Performance of the Upper Limb module for Duchenne muscular dystrophy.
    Mayhew A; Mazzone ES; Eagle M; Duong T; Ash M; Decostre V; Vandenhauwe M; Klingels K; Florence J; Main M; Bianco F; Henrikson E; Servais L; Campion G; Vroom E; Ricotti V; Goemans N; McDonald C; Mercuri E;
    Dev Med Child Neurol; 2013 Nov; 55(11):1038-45. PubMed ID: 23902233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures.
    Henricson EK; Abresch RT; Cnaan A; Hu F; Duong T; Arrieta A; Han J; Escolar DM; Florence JM; Clemens PR; Hoffman EP; McDonald CM;
    Muscle Nerve; 2013 Jul; 48(1):55-67. PubMed ID: 23649481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genotype characterization and delayed loss of ambulation by glucocorticoids in a large cohort of patients with Duchenne muscular dystrophy.
    Zhang S; Qin D; Wu L; Li M; Song L; Wei C; Lu C; Zhang X; Hong S; Ma M; Wu S;
    Orphanet J Rare Dis; 2021 Apr; 16(1):188. PubMed ID: 33910603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Motor function measure scale, steroid therapy and patients with Duchenne muscular dystrophy.
    Silva EC; Machado DL; Resende MB; Silva RF; Zanoteli E; Reed UC
    Arq Neuropsiquiatr; 2012 Mar; 70(3):191-5. PubMed ID: 22392111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy.
    Ricotti V; Ridout DA; Scott E; Quinlivan R; Robb SA; Manzur AY; Muntoni F;
    J Neurol Neurosurg Psychiatry; 2013 Jun; 84(6):698-705. PubMed ID: 23250964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.